Blenrep combination offers improved survival for those ineligible for lenalidomide
News
Orexa reports promising results in post-operative recovery trial
Dutch biotech’s ORE-001 shows strong potential to prevent ileus after major surgery
UK and US unite to fast-track medical innovation
New MHRA–FDA collaboration aims to boost patient access and AI safety
Herantis advances HER-096 after successful Phase 1b Parkinson’s trial
Positive safety and pharmacokinetic data lay foundation for phase 2 study in 2026
Experts call for urgent action to improve Alzheimer’s diagnosis across Europe
New survey reveals critical gaps in access to testing and timely care
Hikma and Celltrion deepen alliance to boost biosimilar access in MENA
Six new treatments aim to improve patient outcomes across key areas
Sheffield leads UK trial into stem cell treatment for severe scleroderma
UPSIDE study explores early transplant therapy for rare autoimmune disease
AC Immune’s Tau-targeting therapy shows promise in early Alzheimer’s trial
Early-stage study reveals strong immune response and safety profile for ACI-35.030
Xeltis prepares for commercial launch after strong aXess trial results
EU phase 3 data shows major gains in dialysis access performance
North Star shows promise in phase 2 thyroid trial
Acella and Neuvosyn report positive results for investigational DTE therapy
Greater Manchester launches first vaccine studies through new research centre
GM CRDC begins trials to assess real-world effectiveness of respiratory vaccines
Tezspire recommended for EU approval in nasal polyps
CHMP backs AstraZeneca and Amgen’s therapy for chronic rhinosinusitis
Guselkumab receives CHMP backing for subcutaneous induction in ulcerative colitis
EMA opinion supports expanded use of TREMFYA in phase 3 UC treatment
First patient treated in pivotal trial of Parkinson’s cell therapy
BlueRock begins phase 3 study of bemdaneprocel in Parkinson’s disease
European Commission approves ROMVIMZA for TGCT treatment
Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU
